Key Points
- Insider sale: Mo Qatanani sold 136,462 shares on Dec. 4 at an average price of $45.21 for about $6.17M, reducing their holding by 55.6% to 108,964 shares (≈$4.93M).
- Stock and earnings context: SRRK opened at $45.02 with a $4.59B market cap and a 1-year high of $46.98; the company reported a ($0.90) EPS last quarter, missing the ($0.88) estimate, while analysts have an average "Buy" rating and a $48.33 consensus target.
- Institutional ownership: Institutions own roughly 91.08% of Scholar Rock, with Vanguard holding about 4.85M shares (~$155.8M), indicating heavy institutional concentration.
Scholar Rock Holding Corporation (NASDAQ:SRRK - Get Free Report) insider Mo Qatanani sold 136,462 shares of the stock in a transaction on Thursday, December 4th. The stock was sold at an average price of $45.21, for a total transaction of $6,169,447.02. Following the completion of the transaction, the insider directly owned 108,964 shares in the company, valued at $4,926,262.44. The trade was a 55.60% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Mo Qatanani also recently made the following trade(s):
- On Monday, September 22nd, Mo Qatanani sold 3,353 shares of Scholar Rock stock. The shares were sold at an average price of $30.67, for a total value of $102,836.51.
- On Tuesday, September 16th, Mo Qatanani sold 3,178 shares of Scholar Rock stock. The shares were sold at an average price of $33.52, for a total value of $106,526.56.
Scholar Rock Stock Performance
NASDAQ:SRRK opened at $45.02 on Friday. The company has a market capitalization of $4.59 billion, a price-to-earnings ratio of -14.29 and a beta of 0.61. The business has a 50 day moving average of $35.09 and a 200 day moving average of $34.46. The company has a debt-to-equity ratio of 0.41, a current ratio of 6.30 and a quick ratio of 6.30. Scholar Rock Holding Corporation has a 1-year low of $22.71 and a 1-year high of $46.98.
Scholar Rock (NASDAQ:SRRK - Get Free Report) last released its earnings results on Friday, November 14th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.02). During the same quarter in the prior year, the company earned ($0.66) EPS. On average, sell-side analysts predict that Scholar Rock Holding Corporation will post -2.42 earnings per share for the current fiscal year.
Institutional Trading of Scholar Rock
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Scholar Rock by 12.4% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 18,557 shares of the company's stock valued at $597,000 after acquiring an additional 2,051 shares in the last quarter. Federated Hermes Inc. purchased a new stake in shares of Scholar Rock in the 1st quarter worth about $71,000. XTX Topco Ltd purchased a new stake in shares of Scholar Rock in the 1st quarter worth about $422,000. Vanguard Group Inc. boosted its stake in shares of Scholar Rock by 2.1% during the 1st quarter. Vanguard Group Inc. now owns 4,845,205 shares of the company's stock valued at $155,773,000 after purchasing an additional 101,723 shares in the last quarter. Finally, Swiss National Bank increased its position in shares of Scholar Rock by 10.1% during the first quarter. Swiss National Bank now owns 127,000 shares of the company's stock valued at $4,083,000 after buying an additional 11,600 shares during the period. Hedge funds and other institutional investors own 91.08% of the company's stock.
Analysts Set New Price Targets
Several research firms recently issued reports on SRRK. Piper Sandler reduced their price target on Scholar Rock from $52.00 to $51.00 and set an "overweight" rating on the stock in a research report on Wednesday, September 24th. Weiss Ratings restated a "sell (d-)" rating on shares of Scholar Rock in a report on Wednesday, October 8th. Leerink Partners assumed coverage on shares of Scholar Rock in a research note on Monday, September 15th. They issued an "outperform" rating and a $51.00 target price on the stock. JPMorgan Chase & Co. increased their price target on shares of Scholar Rock from $46.00 to $47.00 and gave the company an "overweight" rating in a research report on Tuesday, November 18th. Finally, Jefferies Financial Group initiated coverage on shares of Scholar Rock in a report on Thursday, August 21st. They issued a "buy" rating and a $50.00 price target on the stock. Four investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $48.33.
Check Out Our Latest Research Report on SRRK
Scholar Rock Company Profile
(
Get Free Report)
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
